[go: up one dir, main page]

CO2019008176A2 - Compuestos medicinales y suplementos nutricionales - Google Patents

Compuestos medicinales y suplementos nutricionales

Info

Publication number
CO2019008176A2
CO2019008176A2 CONC2019/0008176A CO2019008176A CO2019008176A2 CO 2019008176 A2 CO2019008176 A2 CO 2019008176A2 CO 2019008176 A CO2019008176 A CO 2019008176A CO 2019008176 A2 CO2019008176 A2 CO 2019008176A2
Authority
CO
Colombia
Prior art keywords
nutritional supplements
medicinal compounds
carriers
various
carrier
Prior art date
Application number
CONC2019/0008176A
Other languages
English (en)
Inventor
Andrea Leone-Bay
Gregory Wesner
Original Assignee
Receptor Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62790943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019008176(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Receptor Holdings Inc filed Critical Receptor Holdings Inc
Publication of CO2019008176A2 publication Critical patent/CO2019008176A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen compuestos medicinales o suplementos nutricionales de cannabinoide sintético en diversas combinaciones de portador. Los portadores pueden incluir aminoácidos grasos N-acilados, potenciadores de penetración y/o diversos otros portadores favorables. Las combinaciones de portador/composición de cannabinoide sintético pueden crear beneficios de administración.
CONC2019/0008176A 2017-01-03 2019-07-29 Compuestos medicinales y suplementos nutricionales CO2019008176A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762441908P 2017-01-03 2017-01-03
PCT/US2018/012261 WO2018129097A1 (en) 2017-01-03 2018-01-03 Medicinal compounds and nutritional supplements

Publications (1)

Publication Number Publication Date
CO2019008176A2 true CO2019008176A2 (es) 2019-08-20

Family

ID=62790943

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0008176A CO2019008176A2 (es) 2017-01-03 2019-07-29 Compuestos medicinales y suplementos nutricionales

Country Status (14)

Country Link
US (2) US20190336472A1 (es)
EP (1) EP3565539A4 (es)
JP (3) JP7281815B2 (es)
KR (1) KR20190103302A (es)
CN (1) CN110121337A (es)
AU (2) AU2018206564B2 (es)
BR (1) BR112019013743A2 (es)
CA (1) CA3049226A1 (es)
CL (1) CL2019001832A1 (es)
CO (1) CO2019008176A2 (es)
EA (1) EA201991641A1 (es)
IL (1) IL267831A (es)
MX (1) MX2019007968A (es)
WO (1) WO2018129097A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11180781B2 (en) * 2016-08-21 2021-11-23 Insectergy, Llc Biosynthetic cannabinoid production methods
US10588974B2 (en) 2016-04-22 2020-03-17 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
JP7281815B2 (ja) * 2017-01-03 2023-05-26 レセプター・ホールディングス・インコーポレイテッド 医薬化合物及び栄養補給剤
CA3089750A1 (en) * 2018-01-29 2019-08-01 Solantech Inc. Methods of treating and/or preventing bedsores using nabilone
MX2021004138A (es) * 2018-10-10 2021-08-05 Tilray Inc Metodos y formulaciones para tratar nauseas y vomito inducidos por quimioterapias.
US12303487B2 (en) 2018-11-19 2025-05-20 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
US11759447B1 (en) 2019-06-26 2023-09-19 RCR BioPharma Compound and method for treating diseases and disorders
CN120919066A (zh) 2019-08-30 2025-11-11 伊维股份有限公司 装载的颗粒、其生产方法及其用途
US12171872B2 (en) 2019-12-09 2024-12-24 Nicoventures Trading Limited Oral compositions and methods of manufacture
CN113040337B (zh) * 2021-04-22 2022-12-09 四川大学 一种熏肉制品及其制备方法
WO2024253228A1 (ko) * 2023-06-09 2024-12-12 주식회사 메타파인즈 악액질 및 근손실의 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU730216B2 (en) 1996-09-01 2001-03-01 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
US20040259952A1 (en) * 2001-11-29 2004-12-23 Richat Abbas Formulations for oral administration of cromolyn sodium
EP2063861B1 (en) 2006-09-15 2015-02-25 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
TR201815752T4 (tr) * 2010-11-25 2018-11-21 Aop Orphan Pharmaceuticals Ag Nabilon ve rastomal metilen beta siklodekstrin içeren hızlı parçalanan bileşimler.
WO2013032934A1 (en) * 2011-08-26 2013-03-07 Aegis Therapeutics, Llc Compositions and methods thereof for oral administration of drugs
CA2845443A1 (en) * 2014-03-04 2015-09-04 Pharmascience Inc. Orally disintegrating tablet of nabilone and method of manufacturing
US10588974B2 (en) 2016-04-22 2020-03-17 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
JP7281815B2 (ja) * 2017-01-03 2023-05-26 レセプター・ホールディングス・インコーポレイテッド 医薬化合物及び栄養補給剤

Also Published As

Publication number Publication date
AU2018206564A1 (en) 2019-08-15
US20230293479A1 (en) 2023-09-21
EP3565539A1 (en) 2019-11-13
JP2024075724A (ja) 2024-06-04
KR20190103302A (ko) 2019-09-04
JP2020503357A (ja) 2020-01-30
AU2018206564B2 (en) 2023-12-07
BR112019013743A2 (pt) 2020-01-21
CL2019001832A1 (es) 2020-01-31
JP7466238B2 (ja) 2024-04-12
CN110121337A (zh) 2019-08-13
US20190336472A1 (en) 2019-11-07
EP3565539A4 (en) 2020-08-12
IL267831A (en) 2019-09-26
CA3049226A1 (en) 2018-07-12
JP2023071697A (ja) 2023-05-23
AU2024201078A1 (en) 2024-03-07
WO2018129097A1 (en) 2018-07-12
EA201991641A1 (ru) 2020-03-10
JP7281815B2 (ja) 2023-05-26
MX2019007968A (es) 2019-12-05

Similar Documents

Publication Publication Date Title
CO2019008176A2 (es) Compuestos medicinales y suplementos nutricionales
CO2018011299A2 (es) Compuestos medicinales y suplementos nutricionales de base vegetal de rápida acción
CO2019005565A2 (es) Compuestos medicinales y suplementos nutricionales de base vegetal de rápida acción
CO2020005349A2 (es) Composiciones de hierbas con mejor biodisponibilidad
MX2021003939A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
UY37920A (es) Formulaciones cannabinoides sintéticas y a base de plantas de inicio rápido y acción prolongada
CL2025000457A1 (es) Inhibidores de ras
CL2023000974A1 (es) Inhibidores de ras
CO2019009258A2 (es) Administración rápida y controlada de composiciones con efectos séquito restaurados
BR112018012707A2 (pt) inibidores da interação de menin-mll
MX2018004515A (es) Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
MX2017015467A (es) Metodos y composiciones para inhibir la interaccion de menina con proteinas de mll.
BR112015019064A8 (pt) uso de uma composição compreendendo nanopartículas compreendendo paclitaxel e uma albumina para o tratamento de melanoma e kit
MX2018003700A (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de higado graso, y uso de los mismos.
MX2018010971A (es) Compuestos y métodos para modular la tirosina cinasa de bruton.
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
CO2020006907A2 (es) Péptidos antimicrobianos y métodos para usarlos
EA202190633A1 (ru) Лекарственные формы для применения в педиатрии, способы получения и применения
ECSP21017326A (es) Composiciones alimenticias y composiciones de aditivos para piensos para especies de acuicultura
ECSP15009928A (es) Producto de pienso y/o ingrediente de pienso
EA201892376A1 (ru) Комбинированный состав трех противовирусных соединений
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.
EA202091403A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
AR105728A1 (es) Lisobactina para su uso en el tratamiento de la mastitis bovina
UA95002U (xx) Кормова добавка з пребіотичною дією "пребіолакт"